Christopher J. Moreau, CEO of Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) presents to investors at the Proactive One2One virtual investment forum. Algernon is a clinical stage pharmaceutical development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). The company identifies drugs that are used to treat one condition but repurposes them for different treatments. Most recently the company is focusing its efforts on repurposing ifenprodil (NP-120) as a potential COVID-19 treatment. Algernon believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively.
Algernon Pharmaceuticals Inc presents at the Proactive One2One virtual investment forum
Quick facts: Algernon Pharmaceuticals Inc.
Price: 0.37 CAD
Market Cap: $51.87 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...FOR OUR FULL DISCLAIMER CLICK HERE